Back to TEV.F Overview
FRA · Valuation Lab
TEV.F
Teva Pharmaceutical Industries Limited
Last$29.20
Market cap34B
EV/EBITDA11.1x
Intrinsic value
$23.96
MoS -21.9% · Overvalued
Assuming 12.8% FCF margin and -0.8% Y1–5 growth.
Upside to price
EV (DCF)41.2B
Terminal share63%
Expected IV$26.60
Probability weights
Projected free cash flows
Stage FCF path with present values · terminal 63% of EV
PV of stage FCFs15.3B
PV of terminal value25.8B
Enterprise value41.2B
Net cash / (debt)-13.2B
Equity value27.9B
Intrinsic value / share$23.96
| Year | Revenue | FCF | PV | DF |
|---|---|---|---|---|
| Y1 | 17.2B | 2.2B | 2.1B | 93.3% |
| Y2 | 17B | 2.2B | 1.9B | 87.1% |
| Y3 | 16.9B | 2.2B | 1.8B | 81.2% |
| Y4 | 16.8B | 2.1B | 1.6B | 75.8% |
| Y5 | 16.6B | 2.1B | 1.5B | 70.7% |
| Y6 | 17B | 2.2B | 1.4B | 66.0% |
| Y7 | 17.3B | 2.2B | 1.4B | 61.6% |
| Y8 | 17.7B | 2.3B | 1.3B | 57.5% |
| Y9 | 18B | 2.3B | 1.2B | 53.6% |
| Y10 | 18.4B | 2.4B | 1.2B | 50.0% |
| Terminal | — | — | 25.8B | — |
Educational DCF model only — not financial advice. Terminal value and assumptions dominate results; verify filings and run your own diligence.